A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The drug combination doubled the number of patients whose cancer had not progressed after one year from 14% to 28%, according to the study.
by via Latest Science News -- ScienceDaily
by via Latest Science News -- ScienceDaily
No comments:
Post a Comment